The role of FibroScan in the era of metabolic (dysfunction)-associated fatty liver disease
Künye
Yilmaz, Y., & Kaya, E. (2023). The role of FibroScan in the era of metabolic (dysfunction)-associated fatty liver disease. Hepatology forum, 4(2), I–II. https://doi.org/10.14744/hf.2022.2022.0044Özet
Among chronic liver conditions, metabolic (dysfunction)-associated
fatty liver disease (MAFLD) ranks as the most frequent. With a worldwide prevalence of 37%, the global burden of MAFLD is large and
growing.
